Lantheus LNTH 深 沪
等待开盘 08-20 09:30:00 美东时间
100.48
+0.220
+0.22%
华盛通- 最 高100.72
- 今 开100.35
- 成交量 125.41万股
- 最 低 100.225
- 昨 收 100.26
- 总市值 65.59亿
- 52周最高 111.86
- 市盈率 静 29.44
- 换手率 1.92%
- 52周最低 49.67
- 委 比 90.63%
- 总股本 6527.24万
- 历史最高 126.8899
- 量 比 0.83
- 振 幅 0.49%
- 历史最低 1.76
- 每 手 1
- 风险率 18.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
On Friday, the U.S. Food and Drug Administration (FDA) approved Lantheus Holdings Inc.’s (NASDAQ:LNTH) Tauklarify (florquinitau F 18 injection). Also known as MK-6240, this radiodiagnostic agent is designed for positron emission tomography (PET) scans of the brain in adult patients experiencing cogn...
08-15 00:11
Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ ...
08-14 20:02
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Lantheus Holdings announced the U.S. FDA approval of TAUKLARIFY (florquinitau F 18 injection) for PET brain imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify tau neurofibrillary tangle pathology. The approval is supported by clinical studies showing high positive and negative percent agreement and strong inter-reader consistency. TAUKLARIFY is safe and effective, with common adverse reactions includin...
08-14 12:00
80亿核药世纪并购！两大核药巨头凑出完整产业链
（来源：求实药社） 核药行业的竞争攀升至全新维度。 8月3日，Curium官宣与Lantheus达成合并协议，交易总对价最高可达80亿美元，创下核药赛道有史...
08-13 17:26
财报速睇 | Lantheus 2026财年Q2营收3.88亿美元，同比增长2.7%；归母净利润0.75亿美元，同比下滑4.7%
华盛资讯8月6日讯，Lantheus公布2026财年Q2业绩，公司Q2营收3.88亿美元，同比增长2.7%，归母净利润0.75亿美元，同比下滑4.7%。
08-06 20:24
财报速睇 | Lantheus 2026财年Q2营收3.88亿美元，同比增长2.7%；归母净利润0.75亿美元，同比下滑4.7%
华盛资讯8月6日讯，Lantheus公布2026财年Q2业绩，公司Q2营收3.88亿美元，同比增长2.7%，归母净利润0.75亿美元，同比下滑4.7%。
08-06 20:04
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
08-04 01:41
Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders
Global investment firm CapVest Partners LLP is doubling down on nuclear medicine after portfolio company Curium agreed to acquire Lantheus Holdings Inc. (NASDAQ:LNTH) in a deal valued at up to $8 billion. Kate Briant, Chair of Curium’s Board of Directors and a Senior Partner at CapVest, said the acq...
08-04 00:53
